background
ongo
middl
east
respiratori
syndrom
coronaviru
merscov
infect
pose
threat
public
health
worldwid
make
understand
mer
pathogenesi
develop
effect
medic
countermeasur
mcm
urgent
method
use
homozyg
heterozyg
human
dipeptidyl
peptidas
transgen
mice
studi
effect
merscov
infect
specif
determin
valu
lethal
dose
ld
merscov
strain
mice
compar
correl
level
solubl
express
suscept
explor
recombin
r
effect
mcm
mer
infect
result
mice
unexpectedli
resist
mice
merscov
infect
judg
increas
ld
reduc
lung
viral
infect
attenu
morbid
mortal
reduc
histopatholog
addit
resist
merscov
infect
directli
correl
increas
serum
serum
viru
neutral
activ
final
administr
led
reduc
lung
viru
titer
histopatholog
conclus
studi
suggest
serum
level
play
role
mer
pathogenesi
demonstr
potenti
treatment
option
mer
addit
offer
valid
pair
tg
mice
strain
character
effect
mer
pathogenesi
middl
east
respiratori
syndrom
mer
emerg
infecti
diseas
caus
coronaviru
merscov
first
identifi
saudi
arabia
sinc
spread
mostli
surround
countri
result
laboratoryconfirm
case
infect
death
approxim
june
pandem
potenti
infect
call
better
understand
mer
pathogenesi
develop
effect
medic
countermeasur
mcm
human
like
human
cov
merscov
use
exoaminopeptidas
human
dipeptidyl
peptidas
entri
receptor
infect
permiss
cell
also
known
involv
mani
physiolog
function
via
ubiquit
express
varieti
tissu
propens
interact
adenosin
deaminas
import
regulatori
molecul
immun
system
intrins
proteolyt
activ
cleav
mani
biolog
activ
peptid
protein
contain
prolin
alanin
penultim
posit
express
type
ii
transmembran
glycoprotein
primarili
endotheli
epitheli
cell
subset
immun
cell
also
present
function
intact
solubl
form
circul
bodi
fluid
wild
type
mice
suscept
merscov
establish
heterozyg
transgen
tg
mous
model
global
express
studi
mer
pathogenesi
develop
mcm
merscov
infect
ensur
steadi
costeffect
suppli
anim
tg
mous
model
homozyg
express
design
tg
mice
develop
mate
mice
use
breeder
gener
offspr
genotyp
tg
mice
function
merscov
receptor
doubl
encod
gene
tg
mice
could
render
suscept
counterpart
merscov
infect
diseas
surpris
found
mice
resist
counterpart
merscov
infect
subsequ
found
increas
express
function
intact
solubl
circul
tg
mice
rel
mice
associ
increas
resist
might
least
part
account
seemingli
counterintuit
find
suscept
merscov
infect
notion
support
studi
show
elev
level
brought
administr
recombin
result
increas
resist
recipi
mice
merscov
togeth
result
indic
manipul
might
serv
strategi
counteract
merscov
infect
diseas
human
transgen
mice
establish
previous
report
breeder
mice
deriv
mate
parent
mice
homozygos
determin
quantit
polymeras
chain
reaction
analysi
tail
dna
data
shown
verifi
subsequ
mate
wildtyp
wt
mice
mice
uniformli
yield
heterozyg
offspr
select
breeder
interbreed
mice
produc
addit
mice
wherea
backcross
wt
mice
gener
mice
vitro
anim
studi
involv
infecti
merscov
conduct
biosafeti
level
laboratori
anim
facil
galveston
nation
laboratori
accord
approv
protocol
guidelin
regul
nation
institut
health
nih
associ
assess
accredit
laboratori
anim
care
aaalac
detail
methodolog
viral
infect
isol
infect
lung
brain
determin
infecti
viral
load
establish
routin
use
laboratori
origin
stock
merscov
strain
gift
heinz
feldmann
nih
hamilton
mt
ron
fouchier
erasmu
medic
center
rotterdam
netherland
expand
vero
cell
time
consecut
passag
contain
titer
approxim
cell
cultur
infecti
dose
tcid
ml
viru
use
throughout
studi
lethal
dose
ld
valu
mice
determin
use
tradit
viru
dilut
assay
reedmuench
method
previous
describ
briefli
group
young
week
old
month
mice
inocul
via
intranas
rout
dosag
merscov
decrement
tcid
volum
mice
monitor
daili
clinic
manifest
weight
loss
mortal
least
day
postinfect
dpi
ld
valu
strain
mice
estim
base
ratio
surviv
mice
total
inocul
mice
previous
describ
surviv
day
also
evalu
specif
antibodi
respons
merscov
receptor
bind
domain
rbd
protein
enzymelink
immunosorb
assay
elisa
show
specif
antibodi
rbd
consid
merscov
infect
quantifi
circul
sera
naiv
mice
commerci
elisabas
assay
use
follow
manufactur
instruct
ebiosci
catalog
absorb
nm
plate
read
elisa
plate
reader
molecular
devic
elisabas
vero
cellbas
microneutr
assay
previous
describ
use
determin
titer
merscov
rbdspecif
serum
igg
neutral
antibodi
tg
mice
respons
merscov
infect
purifi
insect
cellderiv
human
ectodomain
residu
genbank
access
contain
ntermin
human
signal
peptid
ctermin
tag
previous
describ
character
prepar
use
treatment
studi
test
bind
specif
rbd
protein
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
rbd
gener
gift
dr
du
jiang
new
york
blood
center
ny
determin
elisabas
assay
determin
capac
inhibit
merscov
infect
vitro
initi
use
standard
microneutr
procedur
cytopath
effect
cpe
inhibit
endpoint
assay
reveal
dosedepend
reduct
cpe
hour
rang
less
gradual
increas
approxim
addit
standard
microneutr
assay
cpe
endpoint
measur
antivir
effect
use
viru
yield
dilut
express
log
tcid
ml
effect
inhibit
merscov
infect
tg
mice
determin
use
mice
pilot
studi
differ
batch
show
similar
ident
bind
capac
merscov
rbd
vitro
neutral
activ
briefli
group
mice
n
per
group
treat
twice
either
phosphatebuff
salin
pb
control
via
intraperiton
rout
hour
hour
hour
hour
infect
intranas
tcid
merscov
mice
sacrif
dpi
assess
infecti
viral
load
histopatholog
lung
inflat
lung
specimen
brain
tissu
fix
neutral
buffer
formalin
hour
paraffin
embed
process
routin
hematoxylin
eosin
stain
h
e
assess
histopatholog
previous
describ
statist
analys
perform
use
graphpad
prism
softwar
neutral
antibodi
titer
viru
titer
averag
group
mice
compar
use
student
test
anova
other
indic
initi
comparison
suscept
mice
merscov
determin
ld
valu
mice
month
age
previous
describ
function
receptor
merscov
anticip
mice
might
least
equal
permiss
mice
merscov
infect
surpris
found
mice
resist
mice
indic
ld
valu
tcid
merscov
mice
respect
confirm
seemingli
counterintuit
find
rule
potenti
effect
age
gender
repeat
studi
use
age
week
old
sexmatch
tg
mice
genotyp
shown
figur
repres
independ
perform
experi
confirm
differ
valu
mice
tcid
merscov
respect
indic
mice
resist
ageand
sexmatch
counterpart
merscov
infect
use
sera
collect
dpi
strain
tg
mice
surviv
lower
challeng
dosag
quantifi
merscov
rbdspecif
igg
antibodi
elisa
found
infect
occur
tg
mice
strain
infect
rate
given
tcid
similar
mice
mice
tcid
strain
greater
mice
mice
tcid
differ
infect
rate
consist
increas
resist
mice
describ
earlier
verifi
differ
suscept
merscov
infect
infect
intranas
n
n
tg
mice
equal
dose
merscov
tcid
per
mous
monitor
daili
morbid
weight
loss
mortal
three
mice
strain
unless
indic
otherwis
euthan
dpi
assess
infecti
viral
titer
histopatholog
lung
brain
contrast
mice
exhibit
mark
weight
loss
start
dpi
death
dpi
data
shown
infect
mice
exhibit
minim
weight
chang
uniformli
surviv
dpi
experi
termin
figur
viral
load
measur
dpi
readili
recov
infecti
viru
lung
brain
mice
examin
lung
mice
although
usual
recov
viru
lung
mice
effort
recov
infecti
viru
lung
brain
specimen
strain
tg
mice
dpi
unsuccess
data
shown
howev
abl
retriev
infecti
viru
brain
lung
sole
survivor
mice
surviv
dpi
viru
titer
brain
g
singl
mous
titer
significantli
higher
averag
g
mice
figur
abil
recov
infecti
viru
lung
approxim
day
earlier
brain
consist
pattern
kinet
tissu
distribut
merscov
infect
tg
mice
previous
report
also
compar
histopatholog
lung
brain
prime
target
merscov
infect
tg
mice
although
infect
mice
elicit
mildtomoder
histopatholog
chang
within
lung
dpi
dose
tcid
merscov
infect
earlier
studi
infect
mice
exhibit
reduc
lung
histopatholog
data
shown
brain
histopatholog
dpi
sole
survivor
infiltr
mononuclear
cell
mening
figur
perivascular
cuf
figur
microgli
nodul
figur
microhemorrhag
figur
cell
death
junction
gray
white
matter
figur
mice
collect
signific
differ
strain
mice
ld
valu
seroconvers
rate
viral
load
weight
loss
histopatholog
support
notion
mice
resist
mice
merscov
infect
sera
naiv
human
dipeptidyl
peptidas
mice
contain
significantli
higher
level
solubl
exhibit
higher
level
neutral
antibodylik
activ
naiv
mice
group
least
ageand
sexmatch
transgeneneg
litterm
subject
retroorbit
bleed
assess
content
use
commerci
avail
elisa
kit
quantifi
specif
vs
p
test
b
sera
obtain
naiv
mice
n
mice
n
subject
standard
vero
microneutr
test
determin
potenti
neutral
merscov
data
present
geometr
mean
neutral
titer
gmt
log
neutral
titer
nt
dilut
sera
approxim
log
p
test
mannwhitney
rank
sum
test
compar
mice
gmt
titer
mice
uniformli
limit
detect
abbrevi
elisa
enzymelink
immunosorb
assay
merscov
middl
east
respiratori
syndromeassoci
coronaviru
dot
line
limit
detect
tg
mice
could
differ
therebi
contribut
differ
suscept
merscov
infect
use
commerci
elisabas
analysi
unabl
detect
ageand
sexmatch
litterm
howev
shown
figur
repres
independ
perform
studi
averag
mean
sd
detect
n
mice
n
respect
retain
bind
specif
merscov
rbd
protein
significantli
differ
express
sera
strain
tg
mice
p
prompt
us
examin
elev
express
might
relat
higher
resist
merscov
infect
possibl
act
like
decoy
bind
merscov
rbd
prevent
viru
infect
use
microneutr
test
note
neutral
titer
nt
express
geometr
mean
titer
gmt
mice
respect
p
compar
mice
uniformli
limit
detect
ie
figur
significantli
higher
express
better
neutral
activ
might
contribut
increas
resist
mice
merscov
infect
explor
whether
increas
express
might
increas
resist
naiv
mice
merscov
infect
use
limit
amount
insect
cellderiv
known
specif
bind
rbd
merscov
sarscov
neutral
merscov
vitro
dosedepend
manner
figur
administ
via
intraperiton
rout
mice
hour
hour
hour
hour
infect
tcid
merscov
effect
merscov
infect
assess
dpi
use
titer
infecti
viru
within
lung
end
point
pilot
studi
pbstreat
mice
exhibit
moder
titer
live
viru
unabl
recov
infecti
viru
mice
tabl
experi
encourag
preliminari
data
gener
anoth
batch
shown
inhibit
merscov
infect
dosedepend
manner
figur
repeat
experi
gave
group
mice
either
pb
control
hour
hour
viru
infect
determin
administr
would
increas
circul
level
serum
level
mice
prior
hour
first
administr
challeng
merscov
measur
found
titer
hour
tg
mice
given
versu
similar
pbstreat
mice
versu
howev
mice
treat
show
significantli
increas
titer
hour
treatment
increas
p
test
result
suggest
increas
serum
level
achiev
administr
dosedepend
manner
addit
viral
load
within
lung
dpi
pulmonari
histopatholog
examin
investig
effect
merscov
infect
unlik
first
studi
treatment
dose
hour
hour
fulli
protect
merscov
infect
abl
recov
reduc
titer
infecti
viru
mice
given
second
batch
compar
pbstreat
control
p
elisa
plate
precoat
rbd
protein
merscov
sarscov
use
determin
bind
specif
use
standard
elisabas
assay
absorb
measur
wavelength
nm
b
dosedepend
neutral
activ
differ
batch
merscov
modifi
vero
microneutr
test
viru
yield
use
quantifi
neutral
antibodylik
capac
describ
earlier
method
p
p
abbrevi
elisa
enzymelink
immunosorb
assay
od
optic
densiti
tcid
cell
cultur
infecti
dose
test
howev
shown
tabl
experi
titer
infecti
viru
mice
treat
significantli
reduc
averag
mean
se
control
mice
tcid
g
p
test
find
consist
reduc
potenc
batch
shown
figur
howev
histopatholog
mice
treat
high
dose
ie
reduc
well
compar
pb
control
data
shown
studi
found
mice
resist
mice
merscov
infect
evidenc
approxim
increas
ld
reduc
infecti
viral
yield
seroconvers
rate
well
less
weight
loss
lower
mortal
ageand
sexmatch
counterpart
figur
also
found
mice
significantli
higher
level
circul
mice
figur
moreov
higher
serum
level
exhibit
higher
titer
neutral
activ
merscov
vero
cellbas
assay
final
show
administr
function
activ
protein
figur
enabl
mice
better
resist
merscov
infect
dosedepend
manner
tabl
find
accord
increas
level
circul
taken
togeth
result
support
notion
increas
level
potenti
option
counteract
merscov
infect
diseas
human
ubiquit
express
mani
type
cell
tissu
well
character
critic
involv
regul
mani
import
physiolog
function
part
intrins
enzymat
activ
propens
interact
key
regulatori
molecul
immun
system
function
receptor
mediat
entri
merscov
permiss
host
cell
membraneassoci
play
pivot
role
merscov
infect
diseas
howev
specif
role
might
mer
pathogenesi
remain
much
less
understood
level
vari
significantli
even
among
healthi
individu
shown
intens
express
circul
along
intrins
enzymat
activ
could
factor
dictat
sever
mani
human
diseas
includ
malign
autoimmun
inflammatori
diseas
diabet
mellitu
metabol
syndrom
chronic
infecti
diseas
aid
hepat
c
recent
report
serum
level
express
confirm
mer
patient
significantli
reduc
compar
healthi
individu
howev
suggest
reduc
level
could
serv
biomark
suscept
requir
knowledg
regard
level
mer
case
onset
infect
diseas
addit
studi
therapeut
valu
either
signific
resist
factor
potenti
countermeasur
merscov
human
warrant
note
solubl
form
viral
receptor
sever
virus
includ
caus
sarscov
rhinoviru
hiv
propos
potenti
effect
antivir
therapeut
show
studi
sera
deriv
naiv
tg
mice
either
strain
especi
possess
detect
neutral
antibodylik
activ
merscov
figur
whether
significantli
higher
express
mice
could
sole
account
greater
resist
merscov
infect
function
receptor
decoy
seem
unlik
took
least
level
higher
approxim
sera
mice
significantli
inhibit
merscov
infect
vero
cell
figur
addit
studi
need
better
understand
protect
mechan
merscov
especi
immun
system
howev
valid
direct
correl
level
suscept
merscov
infect
shown
studi
may
provid
possibl
genet
basi
observ
wide
spectrum
diseas
rang
asymptomat
mildtomoder
sever
infect
death
mer
patient
limit
suppli
shown
independ
perform
proofofprincipl
studi
administr
exogen
might
treatment
mice
n
group
given
either
pb
pb
contain
mous
intraperiton
rout
hour
hour
intranas
challeng
ld
approxim
tcid
merscov
lung
infecti
viral
titer
quantifi
dpi
use
standard
vero
cellbas
infect
assay
b
mean
se
c
none
detect
limit
detect
log
tcid
g
p
test
use
valu
nondetect
sampl
e
p
anova
option
merscov
infect
tabl
addit
studi
requir
determin
increas
level
treatment
could
use
treatment
option
human
mer
studi
present
report
demonstr
use
homozyg
heterozyg
pair
tg
mice
fulli
explor
interact
merscov
infect
diseas
studi
could
lead
identif
novel
molecular
cellular
target
mcm
merscov
infect
diseas
human
financi
support
work
support
nation
institut
allergi
infecti
diseas
nation
institut
health
grant
number
ct
k
fl
potenti
conflict
interest
author
report
conflict
interest
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
